New hope for PAH patients? india study tests sotatercept safety
NCT ID NCT07600723
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tests the safety of a new medicine called sotatercept for adults in India with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs become narrow, making breathing hard. About 30 people will receive sotatercept along with their usual treatments. The goal is to see if adding sotatercept is safe and tolerable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests